DXR

Daxor Corp

Sep 17 • 12:54PM ET

11.37

-0.06 -0.55 %

Healthcare • Medical Instruments & Supplies • USA • NASD

Peers: BIO DHR BRKR TMO MMI QDEL A TRIB VRTX ILMN

Index	-	P/E	31.18	EPS (ttm)	0.36	Insider Own	58.37%	Shs Outstand	4.98M	Perf Week	0.02%
Market Cap	56.40M	Forward P/E	-	EPS next Y	-	Insider Trans	0.13%	Shs Float	2.07M	Perf Month	3.18%
Enterprise Value	56.66M	PEG	-	EPS next Q	-	Inst Own	2.01%	Short Float	1.85%	Perf Quarter	29.35%
Income	1.80M	P/S	52.71	EPS this Y	-	Inst Trans	3.14%	Short Ratio	1.26	Perf Half Y	39.34%
Sales	1.07M	P/B	1.59	EPS next Y	-	ROA	5.12%	Short Interest	0.04M	Perf YTD	47.85%
Book/sh	7.15	P/C	-	EPS next 5Y	-	ROE	5.26%	52W High	11.70 -2.82%	Perf Year	34.56%
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	-54.50% -	ROIC	5.01%	52W Low	6.55 73.59%	Perf 3Y	-11.52%
Dividend Est.	-	EV/EBITDA	30.62	Sales past 3/5Y	62.70% -	Gross Margin	85.67%	Volatility	2.78% 4.67%	Perf 5Y	-16.95%
Dividend TTM	-	EV/Sales	52.95	EPS Y/Y TTM	3.43%	Oper. Margin	173.24%	ATR (14)	0.53	Perf 10Y	47.85%
Dividend Ex-Date	Jan 05, 2018	Quick Ratio	0.19	Sales Y/Y TTM	-97.00%	Profit Margin	168.48%	RSI (14)	55.99	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.19	EPS Q/Q	77.93%	SMA20	2.13%	Beta	-0.11	Target Price	22.00
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	144.72%	SMA50	9.20%	Rel Volume	0.06	Prev Close	11.43
Employees	-	LT Debt/Eq	0.01	Earnings	-	SMA200	30.37%	Avg Volume	30.46K	Price	11.37
IPO	Jul 25, 1983	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	1,383	Change	-0.55%

Date	Action	Analyst	Rating Change	Price Target Change
May-16-19	Initiated	Ascendiant Capital Markets	Buy	$20

Sep-04-25 08:00AM	Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care (GlobeNewswire) +6.59%
Sep-03-25 08:00AM	Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-02-25 08:00AM	Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter (GlobeNewswire) -5.27%
Aug-12-25 08:00AM	Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available (GlobeNewswire) +12.78%
Aug-07-25 07:55AM	Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System (GlobeNewswire)
08:00AM	Loading…
Jul-22-25 08:00AM	Daxor's Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions (GlobeNewswire)
May-14-25 08:00AM	Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal (GlobeNewswire)
May-13-25 08:00AM	Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems (GlobeNewswire)
May-07-25 08:00AM	Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology (GlobeNewswire)
May-06-25 08:00AM	Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance (GlobeNewswire)
Apr-22-25 08:00AM	Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions (GlobeNewswire)
Apr-17-25 08:00AM	Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025 (GlobeNewswire)
Apr-15-25 08:00AM	New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival (GlobeNewswire) -5.83%
Apr-10-25 08:00AM	Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer (GlobeNewswire)
Apr-02-25 08:00AM	Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo (GlobeNewswire)
08:00AM	Loading…
Mar-28-25 08:00AM	Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks (GlobeNewswire)
Mar-04-25 04:55PM	Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024 (GlobeNewswire)
03:53PM	Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025 (GlobeNewswire)
09:00AM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
Feb-28-25 08:00AM	Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center (GlobeNewswire)
Feb-27-25 08:00AM	Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals (GlobeNewswire)
Feb-19-25 08:00AM	Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025 (GlobeNewswire)
Feb-18-25 08:00AM	Daxor to Exhibit at World's Largest Critical Care Conference (GlobeNewswire)
Feb-14-25 08:00AM	Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment (GlobeNewswire)
Feb-13-25 08:00AM	New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care (GlobeNewswire)
Dec-18-24 08:00AM	Daxor Expands Its BVA-100 Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum (GlobeNewswire)
Oct-09-24 08:00AM	DAXOR'S INNOVATIVE BVA-100 BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24 (GlobeNewswire)
Oct-08-24 08:00AM	Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-27-24 05:00PM	Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device (GlobeNewswire)
Sep-19-24 08:00AM	Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024 (GlobeNewswire)
08:00AM	Loading…
Sep-12-24 08:00AM	Newly Published Review Highlights the Pivotal Role of Daxor's Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management (GlobeNewswire)
Sep-05-24 08:00AM	Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee (GlobeNewswire)
Sep-04-24 08:30AM	Leading Central Florida Hospital Implements Daxor's BVA-100 Blood Volume Diagnostic for Heart Failure Patient Care (GlobeNewswire) +5.40%
Sep-03-24 04:05PM	Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter (GlobeNewswire)
12:15PM	Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-29-24 08:00AM	Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network (GlobeNewswire) +21.25%
Aug-06-24 08:00AM	Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer (GlobeNewswire)
Aug-05-24 08:00AM	Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide (GlobeNewswire) +11.96%
Jul-24-24 08:00AM	Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer (GlobeNewswire)
Jul-11-24 08:00AM	Daxor Corporation's BVA-100 Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide (GlobeNewswire)
Jun-18-24 08:00AM	Daxor Corporation to Showcase the Benefits of BVA-100 Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting (GlobeNewswire)
Jun-05-24 08:00AM	Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-16-24 08:00AM	New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion (GlobeNewswire)
Apr-15-24 08:00AM	DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING'24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100 ) (GlobeNewswire)
Apr-10-24 08:00AM	Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital (GlobeNewswire)
Apr-01-24 08:00AM	Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24 (GlobeNewswire)
Mar-28-24 10:38AM	Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-25-24 08:00AM	Daxor Corporation Acquires Volumex and Megatope From Its Existing Supplier Along With Glofil to Enhance Existing Suite of Diagnostics (GlobeNewswire) +6.74%
Mar-22-24 08:00AM	Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024 (GlobeNewswire)
Mar-18-24 02:18PM	Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 (GlobeNewswire)
02:18PM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
Mar-11-24 08:00AM	Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base (GlobeNewswire)
Mar-08-24 08:00AM	Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients (GlobeNewswire)
Feb-26-24 08:00AM	Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference (GlobeNewswire)
Feb-12-24 08:00AM	Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions (GlobeNewswire)
Feb-07-24 08:00AM	Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100 Blood Volume Diagnostic Across the U.S. at Existing Accounts (GlobeNewswire)
Jan-29-24 08:00AM	Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting (GlobeNewswire)
Jan-16-24 08:00AM	Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress (GlobeNewswire)
Jan-09-24 08:00AM	DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES (GlobeNewswire)
Jan-02-24 08:30AM	Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer (GlobeNewswire)
Nov-13-23 08:00AM	New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure Patients (GlobeNewswire) +7.05%
Nov-09-23 08:00AM	Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume (GlobeNewswire)
Oct-13-23 08:00AM	Expert Panelists Advocate Use of Daxor's Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting (GlobeNewswire)
Oct-11-23 08:00AM	New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100 Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting (GlobeNewswire)
Oct-04-23 08:00AM	Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program (GlobeNewswire)
Sep-27-23 08:00AM	Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023 (GlobeNewswire)
Sep-26-23 08:00AM	DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL23 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXORS BLOOD VOLUME DIAGNOSTIC (BVA-100®) (GlobeNewswire)
Sep-11-23 12:00PM	Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients (GlobeNewswire)
Sep-07-23 09:15AM	Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-28-23 04:15PM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
04:05PM	Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023 (GlobeNewswire)
Aug-10-23 08:00AM	JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100® (GlobeNewswire)
Jul-12-23 08:00AM	JACC-HF Study Compares Daxors BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients (GlobeNewswire)
Jul-11-23 08:00AM	Daxor Corporation Announces Further Acquisitions and Increased Utilization of its BVA-100® Blood Volume Diagnostic Throughout the U.S. (GlobeNewswire)
Jul-05-23 08:00AM	Daxor Corporation Awarded $1.1 Million Contract from the United States Defense Health Agency for Added Capabilities to its Point-of-Care Blood Volume Analyzer (GlobeNewswire)
Jun-22-23 04:15PM	Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering (GlobeNewswire)
Jun-20-23 08:00AM	Daxor Corporation to Showcase the Benefits of BVA-100® Guided Care at the American Association of Heart Failure Nurses (AAHFN) 19th Annual Meeting (GlobeNewswire)
Jun-15-23 08:00AM	Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services (GlobeNewswire)
Jun-12-23 08:00AM	Daxor Corporation to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-25-23 03:37PM	Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering (GlobeNewswire)
May-22-23 08:30AM	Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering (GlobeNewswire) -22.30%
May-19-23 04:53PM	Daxor Corporation Announces Proposed Underwritten Public Offering (GlobeNewswire) -6.06%
May-18-23 08:00AM	New Study Demonstrates Clinical Utility of Daxors Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes (GlobeNewswire)
Apr-20-23 08:00AM	New Studies Presented at the 43rd International Society for Heart and Lung Transplant Validate the Applicability of the BVA-100® Blood Test for Patients with Advanced Heart Failure (GlobeNewswire)
Apr-17-23 08:00AM	Daxor Corporation to Exhibit at the MedAxiom Cardiovascular Transforum Conference Spring23 to Advance Awareness and Further Adoption of Daxors Blood Volume Diagnostic (BVA-100®) (GlobeNewswire)
Apr-13-23 08:00AM	Daxor Corporation to Exhibit at the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions (GlobeNewswire)
Mar-27-23 08:00AM	Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100® Blood Volume Diagnostic for Heart Failure Patients (GlobeNewswire) +15.89%
Mar-23-23 08:30AM	New Study Confirms Daxors BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients (GlobeNewswire)
08:00AM	Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients (GlobeNewswire)
Mar-03-23 08:00AM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
Mar-02-23 07:00AM	Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022 (GlobeNewswire) +5.46%
Mar-01-23 08:00AM	Daxor Corporation to Report Fiscal Year 2022 Financial Results on Wednesday, March 1, 2023 and Provide Corporate Update (GlobeNewswire)
Feb-17-23 08:00AM	Daxor Corporation Appoints Linda Cooper, Vice President Project Management (GlobeNewswire)
Jan-19-23 08:00AM	Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member (GlobeNewswire)
Jan-13-23 08:00AM	Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress (GlobeNewswire) -6.22%
Jan-03-23 08:00AM	Newly Published Study Proves Value and Clinical Benefit of Daxors Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure (GlobeNewswire)
Nov-17-22 11:07AM	Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option (GlobeNewswire)
Nov-15-22 08:45AM	Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering (GlobeNewswire) -15.99%
Nov-14-22 05:03PM	Daxor Corporation Announces Launch of Proposed Underwritten Public Offering (GlobeNewswire)
Nov-10-22 08:00AM	Live Webinar by MedAxiom Features Best Practices Using Daxors Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs (GlobeNewswire)

DAXOR Corporation is an innovative medical instrumentation and biotechnology company. DAXOR designed and developed the BVA-100 Blood Volume Analyzer. It is the first instrument approved by the FDA to provide rapid direct measurement of a patient's true blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. The BVA-100 is a semi-automated Blood Volume Analyzer. It is used in conjunction with a single use diagnostic kit. It is the first FDA-approved instrument to provide rapid direct measurement of a patient's blood volume.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Feldschuh Michael Richard	Chief Executive Officer	Apr 04 '25	Buy	7.89	2,063	16,277	212,694	Apr 07 03:23 PM
Michel Robert J	Chief Financial Officer	Mar 10 '25	Buy	8.00	1,000	8,000	17,050	Mar 11 09:36 AM
Feldschuh Michael Richard	Chief Executive Officer	Mar 10 '25	Buy	7.68	3,360	25,805	210,852	Mar 11 09:36 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DXR

Daxor Corp

Upgrade your FINVIZ experience